Akari Therapeutics, Plc (AKTX)

Market Cap	17.17M -57.5%
Revenue (ttm)	n/a
Net Income	-28.05M
EPS	-26.91
Shares Out	1.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,420
Open	15.91
Previous Close	15.45
Day's Range	14.48 - 15.91
52-Week Range	3.02 - 52.00
Beta	1.33
Analysts	Buy
Price Target	26.78 (+78.53%)
Earnings Date	May 19, 2026

About AKTX

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Abizer Gaslightwala
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: AKTX
• Website: https://www.akaritx.com

Analyst Summary

According to 2 analysts, the average rating for AKTX stock is "Buy." The 12-month stock price target is $26.78, which is an increase of 78.53% from the latest price.

Price Target

$26.78

(78.53% upside)

Analyst Consensus: Buy